癌症治疗中的双特异性抗体：靶点选择和监管要求。
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
发表日期：2023 Sep
作者：
Yanze Sun, Xinmiao Yu, Xiao Wang, Kai Yuan, Gefei Wang, Lingrong Hu, Guoyu Zhang, Wenli Pei, Liping Wang, Chengliang Sun, Peng Yang
来源：
Acta Pharmaceutica Sinica B
摘要：
近年来，双特异性抗体（bsAbs）的发展迅猛，涌现出许多新的结构和靶向组合。bsAbs的繁荣导致了美国和中国分别发布了关于其发展的产业指导。然而，目标选择的高度相似性可能影响bsAbs的多样性发展。本综述基于结构和目标选择，对癌症治疗中各种bsAbs进行了分类，并探讨了bsAbs相对于单克隆抗体（mAbs）的优势。通过数据库研究，我们确定了可用的bsAbs组合的偏好，提出了合理的目标选择方案，并警示潜在的医疗资源浪费。此外，我们还比较了美国和中国关于bsAbs的指导意见，以提供参考和发展方向。© 2023 中国制药协会和中国医学科学院药物研究所。Elsevier B.V.进行制作和托管。
In recent years, the development of bispecific antibodies (bsAbs) has been rapid, with many new structures and target combinations being created. The boom in bsAbs has led to the successive issuance of industry guidance for their development in the US and China. However, there is a high degree of similarity in target selection, which could affect the development of diversity in bsAbs. This review presents a classification of various bsAbs for cancer therapy based on structure and target selection and examines the advantages of bsAbs over monoclonal antibodies (mAbs). Through database research, we have identified the preferences of available bsAbs combinations, suggesting rational target selection options and warning of potential wastage of medical resources. We have also compared the US and Chinese guidelines for bsAbs in order to provide a reference for their development.© 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.